Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Lendify has secured new financing of up to SEK 1,000,000,000 from, amongst others, Insight Investment
Mandate

Lendify has secured new financing of up to SEK 1,000,000,000 from, amongst others, Insight Investment

October 22, 2020 Banking and Finance M&A Financial Regulatory

Together with, amongst others, the management of the company, the arranger and legal advisors to the arranger, Vinge has acted for Lendify in the structuring, documenting and execution of the transaction where one of the world’s largest and most well established asset managers, Insight Investment, acted as main investor.

The transaction is reported under the EU securitisation regulation (Regulation (EU) 2017/2402 of the European Parliament and of the Council of 12 December 2017) and is subject to the reporting requirements thereunder.

Vinge’s team mainly consisted of Albert Wållgren, Lionardo Ojeda, Axel Jansson and Rebecka Målquist (Banking and Finance) and Emma Stuart Beck, Caroline Krassén, Lave White (Financial Services) and Hanna Risberg (M&A).

 

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025